Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

This study is testing a combination of two immunotherapy drugs — nivolumab and relatlimab — in patients with melanoma (skin cancer) that has spread to the brain and has not yet been treated with local brain therapy such as radiation or surgery. **You may be eligible if...** - You are 18 or older - You have been diagnosed with melanoma that has confirmed metastases in the brain - At least one brain tumor is 0.5 cm to 3 cm in size and has not received prior radiation - You are in reasonably good health with a life expectancy of more than 12 weeks - You are willing to provide tumor tissue for testing **You may NOT be eligible if...** - All your brain metastases have already been treated with radiation or surgery - You have active autoimmune disease requiring systemic treatment - You have had prior treatment with other checkpoint inhibitor combinations that included LAG-3 or PD-1 targeting - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.